Lifordi Immunotherapeutics, Inc.

Lifordi Immunotherapeutics is a US-based biopharmaceutical company focused on developing targeted antibody-drug conjugates for autoimmune and inflammatory disorders, emphasizing innovative therapeutic solutions. Founded in 2023 in Burlington, US, Lifordi Immunotherapeutics specializes in creating targeted therapies for autoimmune diseases. The company has completed one deal as of November 19, 2025, indicating a strategic approach to developing its product pipeline. The company is led by individuals with notable backgrounds in biotechnology, although specific details about the CEO and founder are not provided.

Lifordi specializes in developing targeted antibody-drug conjugates (ADCs) aimed at treating autoimmune and inflammatory disorders. Their core product offering, LFD-200, is currently undergoing a Phase 1 clinical trial for rheumatoid arthritis, demonstrating the company’s commitment to innovative therapeutic solutions that address significant unmet medical needs. The targeted ADC platform functions by delivering cytotoxic agents directly to diseased cells, maximizing therapeutic efficacy while minimizing systemic toxicity. Lifordi's products are directed towards healthcare providers, particularly in the oncology and immunology sectors, focusing on North America and Europe as key geographical markets.

Lifordi's revenue generation strategy centers around partnerships and collaborations with healthcare institutions and pharmaceutical companies, focusing on the commercialization of their ADC therapies. The business model typically involves agreements for co-development and distribution, where partners may share costs and revenues from successful product launches. Specific transaction structures include B2B arrangements with obligations for milestone payments and royalties based on product sales. The revenue framework encompasses both upfront fees for strategic partnerships and ongoing royalty payments contingent on the clinical and commercial success of their products, particularly LFD-200 as their flagship development.

In November 2025, Lifordi Immunotherapeutics raised an undisclosed amount of venture funding from new investors including Sanofi Ventures, ARCH Venture Partners, 5AM Ventures, and Atlas Venture. The company will use the funding to advance its Phase 1 trial for rheumatoid arthritis and prepare drug supply for Phase 2 studies. Lifordi aims to expand its product line with additional ADC therapies targeting various autoimmune conditions while increasing its market presence in North America and Europe by 2026.